Close Menu

NEW YORK (GenomeWeb) – Personalis said today that it has signed a research agreement with FLX Bio to use its universal cancer immunogenomics ImmunoID Next platform to evaluate therapy-related changes in tumors of advanced cancer patients treated with FLX Bio's FLX475 drug.

As part of the collaboration, FLX Bio will apply the Personalis assay in a patient cohort that is part of a Phase I/II clinical trial evaluating FLX475, a CCR4 antagonist, as monotherapy or in combination with pembrolizumab.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.